Gut microbiota and empagliflozin response in MASLD, Hong Kong
87 stool samples from adult and elderly MASLD patients without diabetes in Hong Kong, in a prospective intervention study examining gut microbiota as a predictor of treatment response to empagliflozin. machine-written summary
87 samples · 87 runs · HK · Age unknown · 2025 · 12.04 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 348 sample values (collection date, country, subject id, timepoint) |
| ✓ Abstract / description | 87 sample values (health condition detail) |
| ✓ Full text | 87 sample values (health condition) · PMC11827547 |
| ✓ Supplementary tables | 90 sample values (age, bmi) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Non-antibiotic pharmaceutical given as the study intervention (metformin design single_arm_before_after · population liver_disease · Empagliflozin treatment, baseline to week 52, in MASLD patients
“non-diabetic MASLD patients who used empagliflozin” — abstract:39950834 (study level; per-sample arms are in the intervention column below)
longitudinal
42 of 45 people sampled more than once (84 samples; median 2, up to 2 per person) · follow-up median 12 mo (max 12 mo) · median interval between samples 12 mo (time from timepoint labels). Schedule stated by the source: “stool at baseline and week 52 (EOT)” (time origin: treatment_start); stated follow-up 12 mo.
Each row is one person (36 shown of 42); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 79 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 87 | 100% | ||||
| country | 87 | 100% | 87 | |||
| health_condition | 87 | 100% | 87 | |||
| subject_id | 87 | 100% | 87 | |||
| collection_date | 87 | 100% | 87 | |||
| health_condition_detail | 87 | 100% | 87 | |||
| timepoint_label | 87 | 100% | 87 | |||
| age_at_collection_days | 45 | 52% | 45 | |||
| bmi | 45 | 52% | 45 |
- Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus. 2025 PMID 39950834 PMC11827547 own_data
Archive description
This study aimed to investigate whether gut microbiota could predict treatment response to pharmacological agents among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus (DM), as data is lacking. Non-diabetic MASLD patients who used empagliflozin were prospectively recruited, and clinical, anthropometric, laboratory assessments and magnetic resonance imaging-proton density fat fraction (MRI-PDFF) were performed from baseline to week 52 (EOT). Stool samples were collected at baseline and at EOT and shotgun DNA metagenomic sequencing performed to profile microbiome. Putative associated bacterial species and metabolic pathways at baseline were identified for treatment response to empagliflozin, defined as MRI-PDFF decline >=30% at EOT from baseline.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.78. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- body site study.description · “Stool samples were collected at baseline”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN45994746 | age_at_collection_days | 23928 | R2 | 0.85 | paper.supp.LIV-45-0-s002.xlsx[data!age] | 65.51 |
| SAMN45994746 | bmi | 25.8 | R2 | 0.85 | paper.supp.LIV-45-0-s002.xlsx[data!bmi] | 25.8 |
| SAMN45994746 | collection_date | 2021 | R1 | 0.90 | biosample.attribute:collection_date | 2021 |
| SAMN45994746 | country | HK | R1 | 0.90 | sample.attr.geo_loc_name | Hong Kong |
| SAMN45994746 | health_condition | liver_disease | R3 | 0.70 | paper.fulltext.methods | adult MASLD patients without DM from the community |
| SAMN45994746 | health_condition_detail | metabolic dysfunction-associated steatotic liver disease (MASLD) without diabetes mellitus | R4 | 0.50 | paper.abstract | non-diabetic MASLD patients |
| SAMN45994746 | subject_id | 01 | R1 | 0.70 | sample.name_rule:alias | G01 |
| SAMN45994746 | timepoint_label | baseline | R1 | 0.70 | sample.name_rule:alias | G01 |
Sequencing
87 runs over 87 samples · mean 12.04 Gbp per run (median 12.04 Gbp, total 1,047.40 Gbp; 87 runs with a base count) · layout PAIRED 87 · platform ILLUMINA 87 · models Illumina NovaSeq 6000 (87) · 91% of runs with a Sandpiper profile · first public 2025-01-12
Downloads
PRJNA1203401.csv.gz (3.7 KB) · parquet (74.7 KB) — all 87 samples, every field with route and confidence · PRJNA1203401_determinations.csv.gz (5.9 KB) — 612 evidence rows